Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

UFS Council elects a new Chairperson
2009-11-22

Judge Ian van der Merwe

The Council of the University of the Free State (UFS) elected Judge Ian van der Merwe as its new Chairperson at its last meeting for this year on Friday, 20 November 2009.

Judge Van der Merwe is an alumnus of the UFS and has been a member of the Council since 9 March 2007. In accepting his appointment, Judge Van der Merwe said that he was honoured and humbled to lead a Council of this calibre. “I will always do what is in the best interest of the UFS and, together with the Council, I will work towards making it an autonomous institution of academic excellence that is non-racial, non-sexist, and where diversity is cherished,” he said.

The election of a new Chairperson and the term of the Chancellor were among the matters discussed during yesterday’s meeting.

Dr Franklin Sonn will retire as Chancellor on 31 December 2009 and the term of office of the current Chairperson of Council, Judge Faan Hancke, will also expire on 31 December 2009. Dr Sonn has been Chancellor since 7 February 2003 and Judge Hancke has been Chairperson of the Council since 1 June 2001.

“I am elated that someone of Judge Van der Merwe’s stature has been elected as Chairperson and will provide him with my full support,” said Prof. Jonathan Jansen, Rector and Vice-Chancellor.

The Council paid tribute to Judge Hancke for the time he dedicated to the UFS, as well as for his leadership, guidance and wisdom to take the institution to where it stands in the current phase of its history. The Council also recognised Judge Hancke for, amongst others, his decision to appoint Prof. Jansen as the first black Rector and Vice-Chancellor, for his role in the implementation of the Transformation Plan and the policy to increase diversity in residences at the UFS, as well as his contribution to the growth of black students.

Judge Hancke thanked the Council for their support and assistance during his term and congratulated Judge van der Merwe on his appointment. “I wish Prof. Jansen and his management team well and hope that they will have the wisdom to solve the problems the institution is facing so that they can focus on the core business of the UFS namely its academia. I know the University can make a tremendous contribution to the country,” he said.

The Council also welcomed the following new members who were present at the meeting: Mr Pule Makgoe, MEC for Education in the Free State; Mr Ndaba Ntsele, Chief Executive Officer of the Pamodzi Group and Mr Willem Louw, Managing Director of Sasol Technology.

The new Chancellor will be elected as soon as the proposed statute is approved by the Council in 2010 and published in the Government Gazette. Prof. Jansen will act as Chancellor for the interim period from 1 January 2010.

Media release
Issued by: Lacea Loader
Deputy Director: Media Liaison
Tel: 051 401 2584
Cell: 083 645 2454
E-mail: loaderl.stg@ufs.ac.za  
21 November 2009
 

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept